Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Seres Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://serestherapeutics.com...
Year Founded: 2010
Status: Public
Industry Sector: HealthTechnology
CEO: Eric D. Shaff, MBA
Number Of Employees: 103
Enterprise Value: $189,985,032
PE Ratio: -0.75
Exchange/Ticker 1: NASDAQ:MCRB
Exchange/Ticker 2: N/A
Latest Market Cap: $125,712,800
BioCentury | Mar 18, 2025
Management Tracks
Zenas names Lisa von Moltke head of R&D and CMO
Plus: CBC’s Lan Kang becomes CEO of Azkarra, and updates from Ionctura, Sunbird and Surf Bio
BioCentury | Dec 18, 2024
Management Tracks
David Apelian becomes CEO of Theolytics
Plus: John McDonough to resign as chairman from BioPorto, and updates from Caris, FibroGen, Akari and Xilio
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Nov 8, 2024
Management Tracks
Moderna expands executive committee, moves commercial under Hoge
Plus: New CFOs at Alkeus, ClaciMedica, and updates from Clairity and Kincell
BioCentury | Aug 14, 2024
Deals
Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging
Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug
BioCentury | Jun 10, 2024
Deals
Deals Report: Elsie, Seres, Marengo build on existing deals to enter new ones
Plus: A takeout offer for Vanda and an ADC deal for ArriVent and Alphamab
BioCentury | Feb 27, 2024
Management Tracks
Pamela Stephenson to head commercial at Disc
Plus: Seres names Marella Thorell as CFO, and updates from Diakonos and NRx
BioCentury | Nov 10, 2023
Management Tracks
New CFO, CMO at TreeFrog
Plus: Metagenomi names Borges CSO and Wapnick CFO, and updates from Teva, Century, Assembly and more
BioCentury | Jun 29, 2023
Deals
Lilly’s CVR-heavy takeout gives lifeline to Sigilon’s diabetes program
Pharma partner pays about $35M, gains control of islet therapy slowed by platform setback; CVRs could drive deal value above $300M
BioCentury | Apr 26, 2023
Finance
April 26 Quick Takes: Orbital’s $270M A round is year’s largest so far
Plus: Medicare to cover Leqembi, if approved; Sangamo restructuring; and updates from Roche, GSK, Seres and more
Items per page:
1 - 10 of 89